Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cost Effectiveness and Resource Allocation
Published in: Cost Effectiveness and Resource Allocation 1/2010

Open Access 01-12-2010 | Research

Prevention, screening and treatment of colorectal cancer: a global and regional generalized cost effectiveness analysis

Authors: Gary M Ginsberg, Stephen S Lim, Jeremy A Lauer, Benjamin P Johns, Cecilia R Sepulveda

Published in: Cost Effectiveness and Resource Allocation | Issue 1/2010

Login to get access

Abstract

Background

Regional generalized cost-effectiveness estimates of prevention, screening and treatment interventions for colorectal cancer are presented.

Methods

Standardised WHO-CHOICE methodology was used. A colorectal cancer model was employed to provide estimates of screening and treatment effectiveness. Intervention effectiveness was determined via a population state-transition model (PopMod) that simulates the evolution of a sub-regional population accounting for births, deaths and disease epidemiology. Economic costs of procedures and treatment were estimated, including programme overhead and training costs.

Results

In regions characterised by high income, low mortality and high existing treatment coverage, the addition of screening to the current high treatment levels is very cost-effective, although no particular intervention stands out in cost-effectiveness terms relative to the others.
In regions characterised by low income, low mortality with existing treatment coverage around 50%, expanding treatment with or without screening is cost-effective or very cost-effective. Abandoning treatment in favour of screening (no treatment scenario) would not be cost effective.
In regions characterised by low income, high mortality and low treatment levels, the most cost-effective intervention is expanding treatment.

Conclusions

From a cost-effectiveness standpoint, screening programmes should be expanded in developed regions and treatment programmes should be established for colorectal cancer in regions with low treatment coverage.
Appendix
Available only for authorised users
Literature
1.
WHO: The World Health Report 2001. In Mental Health; New Understanding, New Hope. WHO Geneva; 2001.
2.
Johns B, Baltussen R, Hutubessy R: Programme costs in the economic evaluation of health interventions. Cost Eff Resour Alloc 2003,1(1):1. 10.1186/1478-7547-1-1PubMedCentralPubMedCrossRef
3.
4.
Adam T, Koomanchap MA: Cost-effectiveness analysis: can we reduce variability in costing methods? Int J Tech Assess Health Care 2002, 19: 407–20. 10.1017/S0266462303000369CrossRef
5.
World Health Organization: Making choices in health: WHO guide to cost-effectiveness analysis. Edited by: Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evanns DB, Murray CJL. WHO Geneva; 2003.
6.
Murray CJ, Evans DB, Acharya A, Baltussen RM: Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ 2000, 9: 235–51. 10.1002/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-OPubMedCrossRef
7.
Hutubessy RC, Baltussen RM, Torres-Edejer TT, Evans DB: Generalised cost-effectiveness analysis: an aid to decision making in health. Appl Health Econ Health Policy 2002, 1: 89–95.PubMed
8.
Baltussen RM, Hutubessy RC, Evans DB, Murray CJ: Uncertainty in cost-effectiveness analysis. Probabilistic uncertainty analysis and stochastic league tables. Int J Technol Assess Health Care 2002, 18: 112–9.PubMed
9.
Hutubessy RC, Baltussen RM, Evans DB, Barendregt JJ, Murray CJ: Stochastic league tables: communicating cost-effectiveness results to decision-makers. Health Econ 2001, 10: 473–7. 10.1002/hec.614PubMedCrossRef
10.
Baltussen RM, Adam T, Tan Torres T, Hutubessy RC, Acharya A, Evans DB: Generalized Cost-Effectiveness Analysis: A Guide. In Global Programme on Evidence for Health Policy. Geneva, World Health Organization; 2002.
11.
Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, Lawes CM, Evans DB: Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 2003, 361: 717–25. 10.1016/S0140-6736(03)12655-4PubMedCrossRef
12.
13.
Baltussen R, Adam T, Tan-Torres Edejer T, Hutubessy R, Acharya A, Evans DB, Murray CJL: Chapter 1. What is Generalised Cost-Effectiveness Analysis? In Making Choices in Health. WHO Guide to Cost-Effectiveness Analysis. Edited by: Tan-Torres Edejer T, Bltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, Murray CJL. WHO Geneva; 2003.
14.
WHO: The World Health Report 2002. In Reducing Risks, Promoting Healthy Life. WHO Geneva; 2002.
15.
16.
17.
Lock K, Pomerleau J, Causer L, McKee M: Inadequate Fruit and Vegetable Consumption. In Draft Sept 2001. European center on Health of Societies in Transition. London School of Hygiene and Tropical Medicine, London;
18.
Herrinton LJ, Selby JV, Friedman GD, Queensberry CP, Weiss NS: Case-control study of digital-rectal screening in relation to mortality from cancer of the distal rectum. Am J Epidemiol 1995, 142: 961–4.PubMed
19.
Pignone M, Rich M, Teutch SM, Berg AO, Lohr KN: Screeing for colrectal cancer in adults at average risk: A summary of evidence for the U.S. preventive services task force. Annals of Internal Medicine 2002, 137: 132–41.PubMedCrossRef
20.
Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, Woolf SH, Glick SN, Ganiats TG, Bond JH, Rosen L, Zapka JG, Olsen SJ, Giardiello FM, Sisk JE, Van Antwerp R, Brown-Davis C, Marciniak DA, Mayer RJ: Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997, 112: 594–642. Published errata in Gastroenterology 1997; 112: 1060 and 1998; 114: 625 10.1053/gast.1997.v112.agast970594PubMedCrossRef
21.
Byers T, Levin B, Rothenberger D, Dodd GD, Smith RA: American Cancer Society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: update 1997. CA Cancer J Clin 1997, 47: 154–60. 10.3322/canjclin.47.3.154PubMedCrossRef
22.
Fletcher RH: The end of barium enemas? N Engl J Med 2000, 342: 1823–4. 10.1056/NEJM200006153422409PubMedCrossRef
23.
Winawer SJ, Stewart ET, Zauber AG, Bond JH, Ansel H, Waye JD, Hall D, Hamlin JA, Schapiro M, O'Brien MJ, Sternberg SS, Gottlieb LS: A comparison of colonoscopy and double-contrast barium, enema for surveillance after polypectomy. National Polyp Study Work Group. N Engl J Med 2000, 342: 1766–72. 10.1056/NEJM200006153422401PubMedCrossRef
24.
25.
Regmi A, Deepak MS, Seale JL, Bernstein J: Cross-Country Analysis of Food Consumption Patterns. In Changing Structiure of Global Food Consumption and Trade/WRS-01–1. Economic Research Service USDA;
26.
Norat T, Lukanova A, Ferrari P, Riboli E: Meat consumption and colorectal cancer risk: an estimate of attributable and preventable fractions. In IARC. Nutrition and Lifestyle: Opportunities for Cancer prevention. Edited by: Riboli E, Lambert R. IARC Scientific Publications No 156. IARC, Lyon, France; 2002:223–5.
27.
Norat T, Lukanova A, Ferrari P, Riboli E: Meat consumption and colorectal cancer risk: dose-response meta-analysis of epidemiological studies. Int J Cancer 2002, 98: 241–56. 10.1002/ijc.10126PubMedCrossRef
28.
IARC Handbooks of Cancer Prevention: Weight Control and Physical Activity. Volume 6. IARC Press, Lyon, France; 2002.
29.
Schatzkin A, Lanza E, Corle D, Lance P, Iber F, Caan B, Shike M, Weissfeld J, Burt R, Cooper MR, Kikendall JW, Cahill J: Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 2000, 342: 1149–55. 10.1056/NEJM200004203421601PubMedCrossRef
30.
Frank L, Andersen M, Schmidt T: Obesity relationship with community design, physical activity, and time spent in cars. Am J Prev Med 2004, 27: 87–96. 10.1016/j.amepre.2004.04.011PubMedCrossRef
31.
Ewing R, Schmid T, Killingworth R, Zlot A, Raudenbusch S: Relationship between urban sprawl and physical activity, obesity, and morbidity. Am J Health Promotion 2003, 18: 47–57.PubMedCrossRef
32.
Surgeon General: The Health Consequences of Smoking. A report of The Surgeon General. Executive Summary CDC, Atlanta; 2004.
33.
IARC Handbooks of Cancer Prevention: Non-Steroidal Anti-Inflammatory Drugs Volume 1. IARC Press, Lyon, France; 1997.
34.
Eichholzer M, Luthy J, Moser U, Fowler B: Folate and the risk of colorectal, breast and cervix cancer: the epidemiological evidence. Swiss Medical Weekly 2001, 131: 539–49.PubMed
35.
Towler BP, Irwig L, Glasziou P, Weller D, Kewenter J: Screening for Colorectal Cancer Using the Faecal Occult Blood Test, Hamoccult (Cochrane Review). In The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd; 2003.
36.
Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, Schuman LM: The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000, 343: 1603–7. 10.1056/NEJM200011303432203PubMedCrossRef
37.
38.
Rex DK, Smith JJ, Ulbright TM, Lehman GA: Screening colonoscopy in asymptomatic average-risk persons with negative fecal occult blood tests. Gastroenterology 1991, 100: 64–7.PubMed
39.
Disario JA, Foutch PG, Mai HD, Pardy K, Manne RK: Prevalence and Malignant Potential of Colorectal Polyps in Asymptomatic, Average-Risk Men. American Journal of Gastroenterology 1991, 86: 941–5.PubMed
40.
Johnson DA, Gurney MS, Volpe RJ, Jones DM, VanNess MM, Chobanian SJ, Avalos JC, Buck JL, Kooyman G, Cattau EL Jr: A prospective study of the prevalence of colonic neoplasms in asymptomatic patients with an age-related risk. Am J Gastroenterol 1990, 85: 969–74.PubMed
41.
Arminski TC, McClean DW: Incidence and Distribution of Adenomateous Polyps of the Colon and Rectum based on 1,000 Autopsy Examinations. Dis Colon Rectum 1964, 19: 249–61. 10.1007/BF02630528CrossRef
42.
Blatt LJ: Polyps of the colon and rectum. Dis Colon Rectum 1961, 4: 277–82. 10.1007/BF02616606CrossRef
43.
Rickert RR, Auerbach O, Garfinkle L, Hammond EC, Frasca JM: Adenomatous lesions of the large bowel. An Autopsy Survey. Cancer 1979, 43: 1847–57. Publisher Full Text 10.1002/1097-0142(197905)43:5<1847::AID-CNCR2820430538>3.0.CO;2-LPubMedCrossRef
44.
Correa P, Strong JP, Reif A, Johnston WD: The Epidemiology of Colorectal Polyps. Cancer 1977, 39: 2258–64. Publisher Full Text 10.1002/1097-0142(197705)39:5<2258::AID-CNCR2820390545>3.0.CO;2-SPubMedCrossRef
45.
Stemmerman GN, Yatani R: Diverticulosis and polyps of the large intestine. Cancer 1973, 31: 1260–70. Publisher Full Text 10.1002/1097-0142(197305)31:5<1260::AID-CNCR2820310535>3.0.CO;2-NCrossRef
46.
47.
Wagner J, Tunis S, Brown M, Ching A, Almeida R: Cost-effectiveness of colorectal cancer screening in average risk adults. In Prevention and early detection of colorectal cancer. Edited by: Young G, Rozen P, Levin B. London. Saunders; 1996:321–56.
48.
Wagner JL, Beheny CJ, Tunis SR, Ching A: US Congress, Office of Technology Assessment, Cost-effectiveness of Colorectal Cancer Screening in Average-Risk Adults, OTA-BP-H-146. Washington, DC: U.S. Government Printing Office; 1995.
49.
Bolin TD, Korman MG, Stanton R, Talley N, Newstead GL, Donnelly N, et al.: Positive cost effectiveness of early diagnosis of colorectal cancer. Colorectal disease 1999, 1: 113–22. 10.1046/j.1463-1318.1999.00028.xPubMedCrossRef
50.
Selby JV, Friedman GD, Queensberry CP, Weiss NS: A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992, 326: 653–7.PubMedCrossRef
51.
Eddy DM, Nugent FW, Eddy JF, Coller J, Gilbertsen V, Gottlieb LS, Rice R, Sherlock P, Winawer S: Screening for colorectal cancer in a high-risk population. Results of a mathematical model. Gastroenterology 1987, 92: 682–92.PubMed
52.
Ladabaum U, Chopra CL, Huang G, Scheiman JM, Chernew ME, Fendrick AM: Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ann Intern Med 2001, 135: 769–81.PubMedCrossRef
53.
Rubin PH, Waye JD, Colonoscopic Polypectomy: A critical review of the literature. Current Gastroenterology Reports 2006, 8;5: 430–433. 10.1007/s11894-006-0030-8CrossRef
54.
Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottleib LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, Panish JF, Ackroyd F, Shike M, Kurtz RC, Hornsby-Lewis L, Gerdes H, Stewart ET, the National Polyp Study Workgroup: Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl JMed 1993, 329;27: 1977–1981. 10.1056/NEJM199312303292701CrossRef
55.
Dixon H, Borland R, Segan C, Stafford H, Sindall C: Public Reaction to Victoria's 2 Fruit 'n' 5 Veg Every Day" Campaign and Reported consumption of Fruit and Vegetables. Preventive medicine 1998, 27: 572–82. 10.1006/pmed.1998.0328PubMedCrossRef
56.
Vijan S, Hwang EW, Hofer TP: Which Colon Cancer Screening test? A comparison of Costs, Effectiveness, and Compliance. The American Journal of Medicine 2001, 111: 593–601. 10.1016/S0002-9343(01)00977-9PubMedCrossRef
57.
58.
Sonnenberg A, Delco F, Inadomi JM: Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 2000, 133: 573–84.PubMedCrossRef
59.
O'Leary BA, Olynyk JK, Neville AM, Platell CF: Cost-effectiveness of colorectal cancer screening: Comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy. Journal of Gastroenterology and Hepatology 2004, 19: 36–47. 10.1111/j.1440-1746.2004.03177.xCrossRef
60.
Frazier AL, Colditz GA, Fuchs CS, Kuntz KM: Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000, 284: 1954–61. 10.1001/jama.284.15.1954PubMedCrossRef
61.
Berchi C, Bouvier V, Réaud J-M, Launoy G: Cost-effectiveness analysis of two strategies for mass screening of colorectal cancer in France. Health Economics 2004, 13: 227–38. 10.1002/hec.819PubMedCrossRef
62.
Khandker RZ, Dulski JD, Kilpatrick JB, Ellis RP, Mitchell JB, Baine WB: A decision model and cost-effectiveness analysis of colorectal cancer screening and surveillance guildelines for average-risk adults. Int J Tech Assess in Health Care 2000, 16;3: 799–810. 10.1017/S0266462300102077CrossRef
63.
Loeve F, Brown ML, Boer R, van Ballegooijen M, van Oortmarssen GJ, Habbema JFD: Endoscopic colorectal-cancer screening, a cost-saving analysis. Journal of the National Cancer Institute 2000, 92: 557–63. 10.1093/jnci/92.7.557PubMedCrossRef
64.
Loeve F, Boer R, van Oortmarssen GJ, van Ballegooijen M, Habbema JDF: The MISCAN-COLON Simulation Model for the Evaluation of Colorectal CancerScreening. Computers and Biomedical Research 1999, 32: 13–33. 10.1006/cbmr.1998.1498PubMedCrossRef
65.
Geul KW, Bosman FT, van Blankenstein M, Grobbee DE, Wilson JHP: Prevention of Colorectal Cancer. Costs and Effectiveness of Sigmoidoscopy. Scand J Gastroenterol 1997,32(Suppl 223):79–87.
66.
Lieberman DA: Cost-effectiveness model for colon cancer screening. Gastroenterology 1995, 109: 1781–90. 10.1016/0016-5085(95)90744-0PubMedCrossRef
67.
Lejeune C, Arveux P, Dancourt V, Fagnani F, Bonithon-Kopp C, Faivre J: A simulation model for evaluating the medical and economic outcomes of screening strategies for colorectal cancer. European Journal of Cancer Prevention 2003, 12: 77–84. 10.1097/00008469-200302000-00012PubMedCrossRef
68.
Ness RM, Holmes AM, Klein R, Dittus R: Cost-Utility of One-Time Colonoscopic Screening for Colorectal Cancer at Various Ages. American Journal of Gastroenterology 2000, 95: 1800–11. 10.1111/j.1572-0241.2000.02172.xPubMedCrossRef
69.
Salkeld G, Young G, Irwig L, Haas M, Glasziou P: Cost-effectiveness analysis of screening by faecal occult blood testing for colorectal cancer in Australia. Aust N Z J Public Health 1996, 20: 138–43. 10.1111/j.1753-6405.1996.tb01807.xPubMedCrossRef
70.
Wagner J, Herdman RC, Wadhwa S: Cost effectiveness of Colorectal Cancer Screening in the Elderly. Annals of Internal Medicine 1991, 115: 807–17.PubMedCrossRef
71.
Tsuji I, Fukao A, Shoji T, Kuwajima I, Sugawara N, Hisamichi S: Cost-effectiveness Analysis of Screening for Colorectal Cancer in Japan. Tohoku J Exp Med 1991, 164: 269–78. 10.1620/tjem.164.269PubMedCrossRef
72.
Leshno M, Halperin Z, Arber N: Cost-effectiveness of Colorectal cancer Screening in the Average Risk Population. Health Care Management Science 2003, 6: 165–74. 10.1023/A:1024488007043PubMedCrossRef
73.
Neilsen AR, Whynes D: Cost-effectiveness of screening for colorectal cancer: A simulation model. IMA Journal of Mathematics Applied in Medicine & Biology 1995, 12: 355–67. 10.1093/imammb/12.3-4.355CrossRef
74.
Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom: UK Colorectal Cancer Screening Pilot Group BMJ 2004,329(7458):133. Epub 2004 Jul 5 10.1136/bmj.38153.491887.7C
75.
Atkin WS, Hart A, Edwards R, McIntyre P, Aubrey R, Wardle J, Sutton S, Cuzick J, Northover JM: Yield of neoplasia, and adverse effects of flexible sigmoidoscopy screening. Gut 1998, 42: 560–5.PubMedCentralPubMedCrossRef
76.
Spratt JS Jr, Spjut HJ: Prevalence and prognosis of individual clinical and pathologic variables associated with colorectal carcinoma. Cancer 1967, 20: 1976–85. Publisher Full Text 10.1002/1097-0142(196711)20:11<1976::AID-CNCR2820201125>3.0.CO;2-MPubMedCrossRef
77.
Mathers CD, Shibuya K, Boschi-Pinto C, Lopez AD, Murray CJL: Global and regional estimates of cancer mortality and incidence by site: 1. Application of regional cancer survival model to estimate cancer mortality distribution by site. BMC Cancer 2002, 2: 36. 10.1186/1471-2407-2-36PubMedCentralPubMedCrossRef
78.
Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ: Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2002, 2: 37. 10.1186/1471-2407-2-37PubMedCentralPubMedCrossRef
79.
80.
Brown ML, Klabunde CN, Mzsliwiec P: Current capacity for endoscopic colorectal cancer screening in the United States: Data from the national cancer institute survey of colorectal cancer screening practices. Am J Med 2003, 115: 129–33. 10.1016/S0002-9343(03)00297-3PubMedCrossRef
81.
Baltussen R, Adam T, Tan-Torres Edejer T, Hutubessy R, Acharya A, Evans DB, Murray CJL: Chapter 4. Health effects. In Making Choices in Health. WHO Guide to Cost-Effectiveness Analysis. Edited by: Tan-Torres Edejer T, Bltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, Murray CJL. WHO Geneva; 2003.
82.
83.
Laparoscopic Resection of Colonic Carcinoma: EAES consensus conference Lisbon, June 2, 2002 Consensus Proceedings.
84.
Morton G, Bowler I: Combined spinal-epidural as an alternative method of anaesthesia for a sigmoid-colectomy. Anaesthesia 2001, 56: 799–820. 10.1046/j.1365-2044.2001.02181-27.xCrossRef
85.
International Drug Price Indicator Guide MSH, Arlington Virginia; 2003.
86.
British National Formulary No 47 Published by the British Medical Association, London and the Royal Pharmaceutical Society of Great Britain, London; 2004.
87.
WHO Commission on MacroEconomics and Health: Macroeconomics and health: investing in health for economic development. In Report of the commission on Macroeconomics and Health. Geneva: World Health Organization; 2001.
88.
Gyrd-Hannsen D: Fecal occult blood tests. A cost-effectiveness analysis. Int J Technol Assess Health Care 1998, 14: 290–301. 10.1017/S0266462300012265CrossRef
89.
Brown ML, Fintor L: Cost-effectiveness of breast cancer screening: preliminary results of a systematic review of the literature. Breast Cancer Res Treat 1993, 25: 113–8. 10.1007/BF00662136PubMedCrossRef
90.
Guittet L, Bouvier V, Mariotte N, Vallee JP, Levillian R, Tichet J, Launoy G: Comparison of a guaiac and an immunochemical feacal occult blood test for the detection of colonic lesions according to lesion type and location. Br J Cancer 2009, 100;8: 1230–5. Epub 2009, Mar 31 10.1038/sj.bjc.6604996CrossRef
91.
Dancourt V, Lejeune C, Lepage C, Gailliard MC, Meny B, Faivre J: Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms. Eur J Cancer 2008,44(15):2254–8. 10.1016/j.ejca.2008.06.041PubMedCrossRef
92.
Castaglione G, Zappa M, Grazzini G, Mazzotta A, Blagini M, Salvadori P, Ciatto S: Immunochemical vs guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer. Br J Cancer 1996, 74: 141–144.CrossRef
93.
Boer R, deKonig HJ, van Ballegooijen M, Maas PJ: Important Influences on Effectiveness and Costs to Be Considered in the Evaluation of Cancer Screening. In Quantitative Methods of Evaluation of Cancer Screening, Arnold, a member of the Hodder Headline Group London. Edited by: Duffy S, Hill C, Esteve J. Oxford University Press, New York; 2001:13–25.
94.
Redaelli A, Cranor CW, Okano GJ, Reese PR: Screening, Prevention and Socioeconomic costs associated with the treatment of colorectal cancer. Pharmacoeconomics 2003, 21: 1213–35. 10.2165/00019053-200321170-00001PubMedCrossRef
Metadata
Title
Prevention, screening and treatment of colorectal cancer: a global and regional generalized cost effectiveness analysis
Authors
Gary M Ginsberg
Stephen S Lim
Jeremy A Lauer
Benjamin P Johns
Cecilia R Sepulveda
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Cost Effectiveness and Resource Allocation / Issue 1/2010
Electronic ISSN: 1478-7547
DOI
https://doi.org/10.1186/1478-7547-8-2

Other articles of this Issue 1/2010

Cost Effectiveness and Resource Allocation 1/2010 Go to the issue

Research

Giving tranexamic acid to reduce surgical bleeding in sub-Saharan Africa: an economic evaluation

Methodology

Measuring the time costs of exercise: a proposed measuring method and a pilot study

Research

Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada

Research

Within a smoking-cessation program, what impact does genetic information on lung cancer need to have to demonstrate cost-effectiveness?

Research

Cost recovery of NGO primary health care facilities: a case study in Bangladesh

Research

Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decisionmaking framework to growth hormone for Turner syndrome patients